Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hayden

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Neurobiology of Disease|February 13, 2026
Corrigendum to 'Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor' [Neurobiology of Disease Volume 124 April 2019 Pages 489-504]Daniel Ryskamp, Lili Wu, Jun Wu, et al.
Journal of Huntington'S Disease|August 23, 2017
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's DiseaseAndrew McGarry, Karl Kieburtz, Victor Abler, et al.
Cell Death & Disease|March 3, 2019
Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1<sup>G93A</sup> ModelAriel Ionescu, Tal Gradus, Topaz Altman, et al.
Autophagy|May 4, 2022
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidineShao-Ming Wang, Hsiang-En Wu, Yuko Yasui, et al.
Molecular Neurobiology|December 19, 2013
IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 miceCarla Lopes, Márcio Ribeiro, Ana I Duarte, et al.
Food and Drug Law Journal|February 11, 2014
Regulatory approval for new pharmacogenomic tests: a comparative overviewYann Joly, Georgia Koutrikas, Anne-Marie Tassé, et al.
Progress in Neurobiology|March 9, 2016
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical researchIris Grossman, Volker Knappertz, Daphna Laifenfeld, et al.
Neurobiology of Disease|September 12, 2006
Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's diseaseShotaro Kishikawa, Jian-Liang Li, Tammy Gillis, et al.
Scientific Reports|July 12, 2017
Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
Journal of Neurochemistry|September 2, 2005
Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's diseaseBruce G Jenkins, Ole A Andreassen, Alpaslan Dedeoglu, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Neurobiology of Disease|February 13, 2026
Corrigendum to 'Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor' [Neurobiology of Disease Volume 124 April 2019 Pages 489-504]Daniel Ryskamp, Lili Wu, Jun Wu, et al.
Journal of Huntington'S Disease|August 23, 2017
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's DiseaseAndrew McGarry, Karl Kieburtz, Victor Abler, et al.
Cell Death & Disease|March 3, 2019
Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1<sup>G93A</sup> ModelAriel Ionescu, Tal Gradus, Topaz Altman, et al.
Autophagy|May 4, 2022
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidineShao-Ming Wang, Hsiang-En Wu, Yuko Yasui, et al.
Molecular Neurobiology|December 19, 2013
IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 miceCarla Lopes, Márcio Ribeiro, Ana I Duarte, et al.
Food and Drug Law Journal|February 11, 2014
Regulatory approval for new pharmacogenomic tests: a comparative overviewYann Joly, Georgia Koutrikas, Anne-Marie Tassé, et al.
Progress in Neurobiology|March 9, 2016
Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical researchIris Grossman, Volker Knappertz, Daphna Laifenfeld, et al.
Neurobiology of Disease|September 12, 2006
Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's diseaseShotaro Kishikawa, Jian-Liang Li, Tammy Gillis, et al.
Scientific Reports|July 12, 2017
Laquinimod treatment in the R6/2 mouse modelGisa Ellrichmann, Alina Blusch, Oluwaseun Fatoba, et al.
Journal of Neurochemistry|September 2, 2005
Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's diseaseBruce G Jenkins, Ole A Andreassen, Alpaslan Dedeoglu, et al.
Pageof 5